Neurotech International (ASX: NTI)

Neurotech International (ASX: NTI) is a medical device and solutions company operating through its wholly-owned subsidiary AAT Research Limited. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Neurotech ASX NTI cannabis treat autism epilepsy ADHD Dolce Cann strain

Neurotech to treat autism, epilepsy and ADHD using Dolce Cann’s proprietary cannabis strains

Neurotech International (ASX: NTI) has collared an exclusive global licence to use Dolce Cann Global’s cannabis strains to treat autism, epileps...
Neurotech International ASX NTI virtual mente clinic

Neurotech launches pilot virtual clinic for autism patients and their carers

Medical solutions developer Neurotech International (ASX: NTI) has launched a pilot version of a virtual clinic which enables doctors to interac...
Neurotech International ASX NTI Mente Autism trial successful

Neurotech International reports positive results in autism clinical trial

Perth-based medical solutions company Neurotech International (ASX: NTI) has confirmed its Mente Autism device specifically developed for childr...
Neurotech International ASX NTI autism effects growing number children

Neurotech on course to alleviate autism effects for growing number of children

Medical solutions developer Neurotech International (ASX: NTI) has received an academia-fuelled boost for its ‘Mente Autism’ device, designed to...
Neurotech International autism research results NTI

Neurotech International reports ‘excellent’ early findings for autism research

Perth-based Neurotech International (ASX: NTI) has surfaced from a trading halt with news of “excellent preliminary findings” for its Mente Auti...